Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases

AAPS Journal

Volumn 17, Issue 4, 2015, Pages 780-787

  Meredith, M Elizabeth ^a,b   Salameh, Therese S ^a,b   Banks, William A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

blood brain barrier; cognition; intranasal; memory

Indexed keywords

ALBUMIN; CYCLODEXTRIN; EXENDIN; EXENDIN 4; GALANIN LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INSULIN; LEPTIN; UNCLASSIFIED DRUG; PEPTIDE; PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; DEGENERATIVE DISEASE; DEPRESSION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESPONSE; ENERGY EXPENDITURE; HUMAN; MIGRAINE; NERVE FIBER TRANSPORT; NONHUMAN; PROTEIN TARGETING; TREATMENT OUTCOME; ANIMAL; BRAIN; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOPHYSIOLOGY; TISSUE DISTRIBUTION;

ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEINS; TISSUE DISTRIBUTION;

EID: 84931571663     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9719-7     Document Type: Article

References (73)

1. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev. 2012;64(7):614–28.
2. Banks WA, During MJ, Niehoff ML. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther. 2004;309(2):469–75.
3. Falcone JA, Salameh TS, Yi X, Cordy BJ, Mortell WG, Kabanov AV, et al. Intranasal administration as a route for drug delivery to the brain: evidence for a unique pathway for albumin. Journal of Pharmacology and Experimental Therapeutics. 2014;351(1):54–60.
4. Nonaka N, Farr SA, Nakamachi T, Morley JE, Nakamura M, Shioda S, et al. Intranasal administration of PACAP: Uptake by brain and regional brain targeting with cyclodextrins. Peptides. 2012;36(2):168–75.
5. Nonaka N, Farr SA, Kageyama H, Shioda S, Banks WA. Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J Pharmacol Exp Ther. 2008;325(2):513–9.
6. Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv. 2012;9(6):566–82.
7. Illum L. Nasal drug delivery—possibilities, problems and solutions. J Control Release. 2003;87(1–3):187–98.
8. Kim TH, Park CW, Kim HY, Chi MH, Lee SK, Song YM, et al. Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice. Biol Pharm Bull. 2012;35(7):1076–83.
9. Khafagy E-S, Morishita M, Takayama K. The role of intermolecular interactions with penetratin and its analogue on the enhancement of absorption of nasal therapeutic peptides. Int J Pharm. 2010;388(1-2):209–12.
10. Chen H, Chen CC, Acosta C, Wu SY, Sun T, Konofagou EE. A new brain drug delivery strategy: focused ultrasound-enhanced intranasal drug delivery. PLoS One. 2014;9(10):e108880.
11. Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007;59(6):478–90.
12. Kozlovskaya L, Abou-Kaoud M, Stepensky D. Quantitative analysis of drug delivery to the brain via nasal route. J Control Release. 2014;189:133–40.
13. Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci. 2009;12(3):288–311.
14. Hanson LR, Frey WH. Intranasal delivery bypasses the blood–brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9 Suppl 3:S5.
15. Hallschmid M, Benedict C, Schultes B, Perras B, Fehm HL, Kern W, et al. Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept. 2008;149(1–3):79–83.
16. Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014;21(2):75–86.
17. Migliore MM, Vyas TK, Campbell RB, Amiji MM, Waszczak BL. Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations. J Pharm Sci. 2010;99(4):1745–61.
18. Morales J. Defining the role of insulin detemir in basal insulin therapy. Drugs. 2007;67(17):2557–84.
19. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9(9):1173–9.
20. Shiba K, Kageyama H, Takenoya F, Shioda S. Galanin-like peptide and the regulation of feeding behavior and energy metabolism. FEBS J. 2010;277(24):5006–13.
21. Shioda S, Kageyama H, Takenoya F, Shiba K. Galanin-like peptide: a key player in the homeostatic regulation of feeding and energy metabolism? Int J Obes (Lond). 2011;35(5):619–28.
22. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, et al. Intranasal insulin improves memory in humans. Psychoneuroendocrinology. 2004;29(10):1326–34.
23. Reger MA, Watson GS, Frey Ii WH, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27(3):451–8.
24. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012;69(1):29–38.
25. Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer’s disease. J Alzheimers Dis. 2013;35(4):789–97.
26. Novakovic ZM, Leinung MC, Lee DW, Grasso P. Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems. Regul Pept. 2009;154(1–3):107–11.
27. Schulz C, Paulus K, Lehnert H. Central nervous and metabolic effects of intranasally applied leptin. Endocrinology. 2004;145(6):2696–701.
28. Fliedner S, Schulz C, Lehnert H. Brain uptake of intranasally applied radioiodinated leptin in Wistar rats. Endocrinology. 2006;147(5):2088–94.
29. Schulz C, Paulus K, Jöhren O, Lehnert H. Intranasal leptin reduces appetite and induces weight loss in rats with diet-induced obesity (DIO). Endocrinology. 2012;153(1):143–53.
30. Nonaka N, Banks WA, Mizushima H, Shioda S, Morley JE. Regional differences in PACAP transport across the blood–brain barrier in mice: a possible influence of strain, amyloid β protein, and age. Peptides. 2002;23(12):2197–202.
31. Rat D, Schmitt U, Tippmann F, Dewachter I, Theunis C, Wieczerzak E, et al. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer’s disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 2011;25(9):3208–18.
32. Merkus FWHM, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PHM, Hermens WAJJ, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev. 1999;36(1):41–57.
33. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171–83.
34. Elsadek B, Kratz F. Impact of albumin on drug delivery—new applications on the horizon. J Control Release. 2012;157(1):4–28.
35. Schnitzer JE. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol Heart Circ Physiol. 1992;262(1):H246–H54.
36. Ginsberg MD, Palesch YY, Hill MD, Martin RH, Moy CS, Barsan WG, et al. High-dose albumin treatment for acute ischaemic stroke (ALIAS). Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. 2013;12(11):1049–58.
37. Hölscher C. Drugs developed for treatment of diabetes show protective effects in Alzheimer’s and Parkinson’s diseases. Sheng Li Xue Bao. 2014;66(5):497–510.
38. Holscher C. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer’s disease. Recent Pat CNS Drug Disc. 2010;5(2):109–17.
39. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson’s disease related to antimuscarinic drugs. Ann Neurol. 2003;54(2):235–8.
40. Gault VA, Hölscher C. GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid. Eur J Pharmacol. 2008;587(1–3):112–7.
41. Ueno H, Mizuta M, Shiiya T, Tsuchimochi W, Noma K, Nakashima N, et al. Exploratory trial of intranasal administration of glucagon-like peptide-1 in Japanese patients with type 2 diabetes. Diabetes Care. 2014;37(7):2024–7.
42. Juréus A, Cunningham MJ, Li D, Johnson LL, Krasnow SM, Teklemichael DN, et al. Distribution and regulation of galanin-like peptide (GALP) in the hypothalamus of the mouse. Endocrinology. 2001;142(12):5140–4.
43. Krasnow SM, Fraley GS, Schuh SM, Baumgartner JW, Clifton DK, Steiner RA. A role for galanin-like peptide in the integration of feeding, body weight regulation, and reproduction in the mouse. Endocrinology. 2003;144(3):813–22.
44. Lawrence CB, Baudoin FM, Luckman SM. Centrally administered galanin-like peptide modifies food intake in the rat: a comparison with galanin. J Neuroendocrinol. 2002;14(11):853–60.
45. Beck B, Pourié G. Ghrelin, neuropeptide Y, and other feeding-regulatory peptides active in the hippocampus: role in learning and memory. Nutr Rev. 2013;71(8):541–61.
46. Borbély E, Scheich B, Helyes Z. Neuropeptides in learning and memory. Neuropeptides. 2013;47(6):439–50.
47. Hökfelt T, Tatemoto K. Galanin: a multitalented neuropeptide. EXS. 2010;102:1–5.
48. Ogren SO, Kehr J, Schött PA. Effects of ventral hippocampal galanin on spatial learning and on in vivo acetylcholine release in the rat. Neuroscience. 1996;75(4):1127–40.
49. McDonald MP, Gleason TC, Robinson JK, Crawley JN. Galanin inhibits performance on rodent memory tasks. Ann N Y Acad Sci. 1998;863:305–22.
50. Yoshitake T, Yoshitake S, Savage S, Elvander-Tottie E, Ogren SO, Kehr J. Galanin differentially regulates acetylcholine release in ventral and dorsal hippocampus: a microdialysis study in awake rat. Neuroscience. 2011;197:172–80.
51. Kinney JW, Starosta G, Holmes A, Wrenn CC, Yang RJ, Harris AP, et al. Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice. Learn Mem. 2002;9(4):178–90.
52. Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer’s disease. Hum Mol Genet. 2009;18(R2):R137–45.
53. Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther. 2012;136(1):82–93.
54. Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–38.
55. Banks WA, Farr SA, Morley JE. Permeability of the blood–brain barrier to albumin and insulin in the young and aged SAMP8 mouse. J Gerontol A: Biol Med Sci. 2000;55(12):B601–B6.
56. Banks WA, Kastin AJ. Differential permeability of the blood–brain barrier to two pancreatic peptides: insulin and amylin. Peptides. 1998;19(5):883–9.
57. Banks WA, Kastin AJ, Pan W. Uptake and degradation of blood-borne insulin by the olfactory bulb. Peptides. 1999;20(3):373–8.
58. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood–brain barrier: saturability at euglycemic doses of insulin. Peptides. 1997;18(9):1423–9.
59. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides. 1996;17(2):305–11.
60. Li XL, Aou S, Oomura Y, Hori N, Fukunaga K, Hori T. Impairment of long-term potentiation and spatial memory in leptin receptor-deficient rodents. Neuroscience. 2002;113(3):607–15.
61. Shanley LJ, Irving AJ, Harvey J. Leptin enhances NMDA receptor function and modulates hippocampal synaptic plasticity. J Neurosci. 2001;21(24):RC186.
62. Farr SA, Banks WA, Morley JE. Effects of leptin on memory processing. Peptides. 2006;27(6):1420–5.
63. Oomura Y, Aou S, Fukunaga K. Prandial increase of leptin in the brain activates spatial learning and memory. Pathophysiology. 2010;17(2):119–27.
64. Steinberg GR, Bonen A, Dyck DJ. Fatty acid oxidation and triacylglycerol hydrolysis are enhanced after chronic leptin treatment in rats. Am J Physiol Endocrinol Metab. 2002;282(3):E593–600.
65. Morley JE, Banks WA. Lipids and cognition. J Alzheimers Dis. 2010;20(3):737–47.
66. Fewlass DC, Noboa K, Pi-Sunyer FX, Johnston JM, Yan SD, Tezapsidis N. Obesity-related leptin regulates Alzheimer’s Abeta. FASEB J. 2004;18(15):1870–8.
67. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A. 1997;94(16):8878–83.
68. Levin N, Nelson C, Gurney A, Vandlen R, de Sauvage F. Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc Natl Acad Sci U S A. 1996;93(4):1726–30.
69. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept. 1992;37(3):285–303.
70. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989;164(1):567–74.
71. Kimball BC, Mulholland MW. Pituitary adenylate cyclase-activating peptide stimulates amylase release and cyclic adenosine monophosphate production in pancreatic acinar cells. Surgery. 1996;120(3):554–9.
72. Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 2014;137(3):779–94.
73. Kinhult J, Adner M, Uddman R, Cardell LO. Pituitary adenylate cyclase-activating polypeptide, effects in the human nose. Clin Exp Allergy. 2003;33(7):942–9.